Bristol-Myers Squibb: HCV Developing World Strategy
 

HCV Developing World Strategy

Amadou Diarra
Amadou Diarra, Head of Global Policy, Advocacy & Government Affairs

Bristol-Myers Squibb recognizes the significant public health challenge that hepatitis C virus (HCV) presents worldwide, including the substantial burden of the disease in the developing world. With more than 80% of the global HCV patient population living in low- and middle-income countries, there is great need for hepatitis C treatment options in these countries. The significant challenges facing many of these countries are not homogeneous and beyond the reach of any one stakeholder to unilaterally address. A particular need exists for governments, non-governmental organizations, civil society and industry to form coalitions to address the challenges.

Bristol-Myers Squibb is continuing to strengthen our efforts to enable global access to Daklinza (daclatasvir). We are employing multiple approaches including tiered pricing in low- and middle-income countries, supplemented by a direct-import program in countries where we do not have plans to commercialize Daklinza. Our tiered pricing model for Daklinza takes into consideration several factors, including countries’ economic development and burden of disease, as well as the commitment of the government to holistically address hepatitis C, including treatment and care. The lowest pricing tier applies to all low-income and least developed countries.

Of significance, we have entered into the first-ever licensing agreement for a hepatitis C medicine with the Medicines Patent Pool (MPP), which will provide a royalty-free license for daclatasvir (Daklinza) in a territory of 112 countries across the globe (see list at right). Nearly two-thirds of all hepatitis C patients in low- and middle-income countries currently reside in the licensing territory, and in developing countries that are not currently included in this footprint, BMS plans to work with authorities and other stakeholders to enable access to Daklinza using other approaches.

 
 



Afghanistan
Algeria
Angola
Azerbaijan
Bangladesh
Belize
Benin
Bhutan
Bolivia
Botswana
Burkina Faso
Burundi
Cambodia
Cameroon
Cape Verde
Central African Republic
Chad
Comoros
Congo,
Democratic Republic
Congo, Republic
Cook Islands
Costa Rica
Cote d'Ivoire
Cuba
Djibouti
Dominica
Dominican Republic
Ecuador
El Salvador
Equatorial Guinea
Eritrea
Ethiopia
Fiji
Gabon
Gambia, The
Georgia
Ghana
Grenada
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
India
Indonesia
Iraq
Jamaica
Kenya
Kiribati
Korea, Dem. Rep.
Laos
Lesotho
Liberia
Libya
Madagascar
Malawi
Maldives
Mali
Marshall Islands
Mauritania
Mauritius
Micronesia
Mongolia
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Nicaragua
Niger
Nigeria
Niue
Pacific Islands (Palau)
Pakistan
Panama
Papua New Guinea
Paraguay
Philippines
Rwanda
Samoa
Sao Tome and Principe
Senegal
Seychelles
Sierra Leone
Solomon Islands
Somalia
South Africa
South Sudan
Sri Lanka
St Lucia
St Vincent and the Grenadines
Sudan
Suriname
Swaziland
Syria
Timor-Leste
Togo
Tonga
Tunisia
Turkmenistan
Tuvalu
Uganda
United Republic of Tanzania
Uzbekistan
Vanuatu
Vietnam
West Bank
Yemen
Zambia
Zimbabwe

November 4, 2015


 
 


You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.
You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.